Scancell raises GBP12 million in total from fundraise
19th Dec 2023 13:35
(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares. Read More
(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares. Read More
Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Raises GBP10.7 million from the placing and subscription of 97.0 million new shares at 11 pence each. The placing is run by Stifel Nicolaus Europe Ltd and WG Partners LLP. Scancell also plans an open offer of shares at the same price to raise up to another GBP2.0 million. Scancell says the placing was oversubscribed and upsized as a result. After the London market close on Thursday, Scancell had announced plans to raise just GBP6 million in the placing. It says the raise was led by "new institutional and life science specialist investors". Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Presents data from first stage of Phase 2 Scope trial at 20th International Congress of the Society for Melanoma Research on Thursday. Trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Company reported mid-September that SCIB1 combined with CPIs showed an 82% objective response rate. Scope trial is currently in its second stage. Scancell says on Friday that in Cohort 1 nine responses were achieved earlier than expected, and probability of second-stage success is around 90% based on current data. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says auditor request additional time to complete standard audit of its results of financial year 2023 that ended on April 30. Cites unforeseen circumstances impacting the audit engagement team. Says audit is substantially complete without any material audit issues. Read More
Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back. Read More
(Alliance News) - Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma. Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Hires Sath Nirmalananthan to be chief financial officer, starting immediately. Nirmalananthan previously was CFO for Europe, Middle East & Africa at Prenetics Ltd, a genomics-driven health sciences company. His appointment at Scancell follows Keith Green's retirement as director of finance. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients. Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Will focus on lead cancer vaccine assets SCIB1 and Modi-1 following encouraging data from clinical trials. Adds phase two single arm scope trial investigating the safety and tolerability of using SCIB1 in combination with checkpoint inhibitors in patients with advanced melanoma is progressing well and notes a potential pathway for a registration trial. Adds it is fully funded to the second half of 2024 due to its increasing focus on the two clinical assets. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Scancell Holdings PLC on Tuesday said that it has completed the monotherapy dose finding arm of its multicentre Phase 1/2 ModiFY clinical trial, designed to treat cancer patients. Read More
(Alliance News) - Scancell Holdings PLC on Monday reported a positive response in its 'Covidity' trial, which aims to deliver needle-free injectable Covid vaccines. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More